The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.

Publication/Presentation Date

8-1-2016

Abstract

The role of consolidative radiotherapy (RT) in patients ≥60 years old with DLBCL in the rituximab era is controversial. We examined the impact on disease control and overall survival by the addition of consolidative RT after completion of chemotherapy, while adjusting for known adverse risk factors. Retrospective chart review from 2004 to 2012 of 83 consecutive patients ≥60 years old with DLBCL treated in the rituximab era, 68 of which had a complete response to chemotherapy, was performed. Amongst patients with a complete response, consolidative RT use was associated with 100% 5-year local control, improved progression-free survival (p = 0.047), and a trend for overall survival (p = .098) on multivariate analysis. Amongst all patients, the use of consolidative RT was associated with improved overall survival (p = 0.03). The use of consolidative RT should be considered for patients ≥60 years old independent of stage and response to chemotherapy.

Volume

57

Issue

8

First Page

1876

Last Page

1882

ISSN

1029-2403

Disciplines

Medicine and Health Sciences | Oncology

PubMedID

26759182

Department(s)

Department of Radiation Oncology

Document Type

Article

Link to Full Text

Share

COinS